- Xconomy.com recently chronicled MSKCC’s expanding efforts in developing medical device technologies.
- An article on the development of the PapGene test for cervical, endometrial and ovarian cancer – by researchers at Johns Hopkins University, MSKCC, and the University of Sao Paolo in Brazil – was published in the journal Science Translational Medicine.
Author Archives: Mark
MSKCC in the News: December 26 – January 9
- Lorus Therapeutics Inc. announced that its Phase I clinical study, conducted at MSKCC and the MD Anderson Cancer Center, of LOR-253 has successfully escalated to the target dose level based on predicted and observed clinical effects without limitation by toxicity.
- MSKCC’s Dr. Peter Bach was quoted in a Reuters article about a study that found that pediatricians-in-training are more likely to plan to go into primary care – rather than a specialty field – if they have lots of debt from college and medical school.
- MSKCC was featured in Health Magazine’s top 12 medical breakthroughs of 2012.
MSKCC in the News: November 22 – December 5
- In a recent project, described in an article published in Nature Biotechnology, researchers from Johns Hopkins and MSKCC reported concrete steps in the use of human stem cells to test how diseased cells respond to drugs.
- Fitch Ratings has assigned an ‘AA’ rating to Memorial Sloan-Kettering Cancer Center’s approximately $400 million revenue bonds, 2012A.
- Researchers from the Catalan Institution for Research and Advanced Studies (ICREA) in Barcelona and MSKCC have found a key pathway that is responsible for metastasis initiation of colorectal tumors to the liver—a frequent metastasis site for this tumor type. The research is published in Cancer Cell.
- Joshua J. Meeks, MD, and colleagues at MSKCC found that if PSA screening were used uniformly—excluding men with PSA levels above 4—only one of 382 TURPs would identify clinically significant PCa, for a total of 390 in the American population in three years, according to an online report in The Journal of Urology.